Pre-conference Session
- Date:
- Time: -
- Track: Clinical Practice
- CME/CE: 4
Additional fee session
Sponsored by the Nurses Section, Teachers Section, Pharmacists Section, Clinical Practice and Models of Care Committee and Education Committee
Moderator: Lisa Granville, MD
This session will include presentations and hands-on skill stations focused on: 1) diagnosis and staging of AD, including when to consider advanced imaging and other biomarkers, 2) therapeutic choices for early AD, including monoclonal antibody therapy eligibility and exclusions, and 3) communication skills centered on the benefits and harms of new therapies integrating with what matters most to the patient. Learning Objectives: (1) diagnose and stage Alzheimer’s disease using a modern clinical, cognitive testing, imaging and biomarker based approach; (2) using the framework of the geriatric 5Ms (mind, medications, mobility, multicomplexity and matters most), analyze the benefits and risks of therapies for MCI and Mild Dementia due to AD; (3) observe and practice communication strategies to counsel patients and care partners on new therapies for AD based on what matters most.
Introduction of Faculty and Orientation to the Session Lisa Granville, MD |
Diagnosing, Staging and Initial Management of MCI and Mild Dementia in the Modern Era Hal Atkinson, MD, MS & Zaldy Tan, MD, MPH, FACP |
Break/Networking |
Therapeutic Choices for Alzheimer’s Disease, Including Eligibility and Safety Monitoring of Amyloid Targeted Therapy Demetra Antimisiaris, PharmD, BCGP, FASCP & K. Gregory Pugh, MD, MSc, FACP |
Break/Networking |
Having the Conversation About Treatment: Benefits, Risks, Alternatives Maura Brennan, MD, AGSF, FACP, FAAHPM & Margaret Wallhagen, PhD, GNP-BC, AGSF, FAAN |
| Break/Networking |
Health System Challenges and Opportunities: The Geriatrics Healthcare Provider’s Role (Panel Q&A) All faculty |